Keywords

• Ibrutinib supplier
• Ibrutinib
• high quality Ibrutinib

Quick Details

• ProName: Ibrutinib manufature
• CasNo: 936563-96-1
• Molecular Formula: C25H24N6O2
• Appearance: Detailed see specifications
• Application: Its an important raw material and inte...
• DeliveryTime: Depend on the quantity client want
• PackAge: According to client's requirements
• Port: SHANGHAI,CHINA
• ProductionCapacity: 50 Metric Ton/Month
• Purity: 99.0%
• Storage: keep sealed and keep from direct light
• Transportation: According to client's requirements
• LimitNum: 10 Gram
• Moisture Content: send with COA
• Impurity: send with COA

Superiority

English Name: ibrutinib            

English alias: 2-propen-1-one, 1 - [(3R) - 3 - [4-amino-3 - (4-phenoxyphenyl) - 1H-pyrazolo [3,4-d] pyrimidin-1-yl] - 1-piperidinyl] -;            

CAS No.: 936563-96-1            

Molecular formula: c25h24n6o2            

Molecular weight: 440.49700            

Introduction: ibrutinib (usan, also known as pci-32765 and marketed under the name imbrufica) is an anticoncer drug targeting B-cell malignancies. It is an arbitrarily administered, selective and valuable inhibitor of the enzyme Bruton's tyrosine kinase (Btk) Ibrutinib was developed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma. It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia. In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma.According to the Wall Street Journal in January 2016 ibrutinib, a specialty drug, cost US$116,600 to $155,400 a year wholesale in the United States. In spite of discounts and medical insurance, the prohibitive price causes some patients to not fill their prescriptions. The company marketing the drug, AbbVie, acquired it in May 2015,  projecting global sales of US$1 billion in 2016 and $5 billion in 2020.

Details

Hangzhou ZeErRui Chemical Co., Ltd. is focused on customization, research and development and production of APIs and advanced intermediates, which can effectively compensate for the deficiencies of traditional CRO and CMO. Priority of high-tech barriers, high value-added, low pollution characteristics of the project, landing the project of innovative non patented route design, difficult process development and rapid industrialization.  Starting from the advantages of combining technology research and stable production, we cooperated with domestic and foreign large pharmaceutical companies in the development of generic drugs and innovative drugs.

It also has hardware facilities and support teams that match the strength of R & D and production: With LCMS, HPLC and other perfect detection means, professional testing team and perfect quality control system; With a pilot base, a stable GMP standard production capacity, and a new GMP workshop is building; With regular financial, legal ERP system and professional sales and logistics team.